Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Fall;42 Suppl 1(Suppl 1):22-41.
doi: 10.1111/jlme.12160.

Clinical integration of next generation sequencing: coverage and reimbursement challenges

Patricia A Deverka  1 , Jennifer C Dreyfus
Affiliations

Clinical integration of next generation sequencing: coverage and reimbursement challenges

Patricia A Deverka et al. J Law Med Ethics. 2014 Fall.

Abstract

Public and private payers face complex decisions regarding whether, when, and how to cover and reimburse for next generation sequencing (NGS)-based tests. Yet a predictable reimbursement pathway is critical both for patient access and incentives to provide the market with better clinical evidence. While preliminary data suggests that payers will use similar evidentiary standards as those used to evaluate established molecular diagnostic tests, the volume and complexity of information generated by NGS raises a host of additional considerations for payers that are specific to this technology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Next Generation Sequencing Process
See this image and copyright information in PMC

References

    1. See Mauer CB, Pirzadeh-Miller SM, Robinson LS, et al. The Integration of Next-Generation Sequencing Panels in the Clinical Cancer Genetics Practice: An Institutional Experience. Genetics in Medicine. 2013;16(5):407–412.Dewey FE, Grove ME, Pan C, et al. Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA. 2014;311(10):1035–1044.

    1. Secretary's Advisory Committee on Genetics Health, and Society, Coverage and Reimbursement of Genetic Tests and Services. 2006
    1. Deverka P, Doksum T, Carlson R. Integrating Molecular Medicine into the US Health-Care System: Opportunities, Barriers, and Policy Challenges. Clinical Pharmacology and. Therapeutics. 2007;82(4):427–434. - PubMed
    1. Wilson C, Schulz S, Waldman S. Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation. Clinical Pharmacology and Therapeutics. 2007;81(2):153–155. - PubMed
    2. Rogowski WH, Grosse SD, Khoury MJ. Challenges of Translating Genetic Tests into Clinical and Public Health Practice. Nature Reviews Genetics. 2009;10(7):489–495. - PubMed
    1. UnitedHealth Center for Health Reform & Modernization . Personalized Medicine: Trends and Prospects for the New Science of Genetic Testing and Molecular Diagnostics. Blue Cross Blue Shield Association, Technology Evaluation Center Criteria; Minnetonka, Minnesota: 2012. [June 18, 2014]. Working Paper 7, available at < http://bcbs.com/blueresources/tec/>.